Advanced Accelerator Applications
39
4
9
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
23.1%
9 terminated/withdrawn out of 39 trials
60.9%
-25.6% vs industry average
10%
4 trials in Phase 3/4
79%
11 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (39)
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
Role: lead
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Role: collaborator
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Role: collaborator
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
Role: collaborator
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
Role: collaborator
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
Role: collaborator
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
Role: lead
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
Role: lead
Post-Authorization Long-Term Safety Study of LUTATHERA
Role: lead
EBRT + Lu-PSMA for N1M0 Prostate Cancer
Role: collaborator
Lutathera and ASTX727 in Neuroendocrine Tumours
Role: collaborator
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Role: collaborator
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
Role: collaborator
Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases
Role: collaborator
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
Role: collaborator
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
Role: lead
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
Role: collaborator
177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma
Role: collaborator
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Role: lead
Radiopharmaceutical Treatment of Advanced Kidney Cancer
Role: collaborator